These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

386 related articles for article (PubMed ID: 23982944)

  • 1. Targeting the androgen receptor with siRNA promotes prostate cancer metastasis through enhanced macrophage recruitment via CCL2/CCR2-induced STAT3 activation.
    Izumi K; Fang LY; Mizokami A; Namiki M; Li L; Lin WJ; Chang C
    EMBO Mol Med; 2013 Sep; 5(9):1383-401. PubMed ID: 23982944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-androgen receptor ASC-J9 versus anti-androgens MDV3100 (Enzalutamide) or Casodex (Bicalutamide) leads to opposite effects on prostate cancer metastasis via differential modulation of macrophage infiltration and STAT3-CCL2 signaling.
    Lin TH; Izumi K; Lee SO; Lin WJ; Yeh S; Chang C
    Cell Death Dis; 2013 Aug; 4(8):e764. PubMed ID: 23928703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TR4 nuclear receptor promotes prostate cancer metastasis via upregulation of CCL2/CCR2 signaling.
    Ding X; Yang DR; Lee SO; Chen YL; Xia L; Lin SJ; Yu S; Niu YJ; Li G; Chang C
    Int J Cancer; 2015 Feb; 136(4):955-64. PubMed ID: 24975468
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ASC-J9
    Lin W; Luo J; Sun Y; Lin C; Li G; Niu Y; Chang C
    Cancer Lett; 2018 Jul; 425():21-30. PubMed ID: 29425687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Infiltrating T cells promote prostate cancer metastasis via modulation of FGF11→miRNA-541→androgen receptor (AR)→MMP9 signaling.
    Hu S; Li L; Yeh S; Cui Y; Li X; Chang HC; Jin J; Chang C
    Mol Oncol; 2015 Jan; 9(1):44-57. PubMed ID: 25135278
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The CCL2-CCR2 Axis Contributes to Migration of Cabazitaxel-resistant Prostate Cancer Cells.
    Natsagdorj A; Izumi K; Hiratsuka K; Naito R; Kadomoto S; Iwamoto H; Yaegashi H; Shigehara K; Nakata H; Mizokami A
    Anticancer Res; 2023 Jun; 43(6):2561-2569. PubMed ID: 37247914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased PrLZ-mediated androgen receptor transactivation promotes prostate cancer growth at castration-resistant stage.
    Li L; Xie H; Liang L; Gao Y; Zhang D; Fang L; Lee SO; Luo J; Chen X; Wang X; Chang LS; Yeh S; Wang Y; He D; Chang C
    Carcinogenesis; 2013 Feb; 34(2):257-67. PubMed ID: 23104178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Infiltrating mast cells enhance prostate cancer invasion via altering LncRNA-HOTAIR/PRC2-androgen receptor (AR)-MMP9 signals and increased stem/progenitor cell population.
    Li L; Dang Q; Xie H; Yang Z; He D; Liang L; Song W; Yeh S; Chang C
    Oncotarget; 2015 Jun; 6(16):14179-90. PubMed ID: 25895025
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elevation of androgen receptor promotes prostate cancer metastasis by induction of epithelial-mesenchymal transition and reduction of KAT5.
    Lin CY; Jan YJ; Kuo LK; Wang BJ; Huo C; Jiang SS; Chen SC; Kuo YY; Chang CR; Chuu CP
    Cancer Sci; 2018 Nov; 109(11):3564-3574. PubMed ID: 30142696
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CCL2/CCR2 axis induces hepatocellular carcinoma invasion and epithelial-mesenchymal transition in vitro through activation of the Hedgehog pathway.
    Zhuang H; Cao G; Kou C; Liu T
    Oncol Rep; 2018 Jan; 39(1):21-30. PubMed ID: 29115520
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting androgen receptor to suppress macrophage-induced EMT and benign prostatic hyperplasia (BPH) development.
    Lu T; Lin WJ; Izumi K; Wang X; Xu D; Fang LY; Li L; Jiang Q; Jin J; Chang C
    Mol Endocrinol; 2012 Oct; 26(10):1707-15. PubMed ID: 22915828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Indole-3-carbinol and 3',3'-diindolylmethane modulate androgen's effect on C-C chemokine ligand 2 and monocyte attraction to prostate cancer cells.
    Kim EK; Kim YS; Milner JA; Wang TT
    Cancer Prev Res (Phila); 2013 Jun; 6(6):519-29. PubMed ID: 23585426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loss of androgen receptor signaling in prostate cancer-associated fibroblasts (CAFs) promotes CCL2- and CXCL8-mediated cancer cell migration.
    Cioni B; Nevedomskaya E; Melis MHM; van Burgsteden J; Stelloo S; Hodel E; Spinozzi D; de Jong J; van der Poel H; de Boer JP; Wessels LFA; Zwart W; Bergman AM
    Mol Oncol; 2018 Aug; 12(8):1308-1323. PubMed ID: 29808619
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemokine CCL2-CCR2 Signaling Induces Neuronal Cell Death via STAT3 Activation and IL-1β Production after Status Epilepticus.
    Tian DS; Peng J; Murugan M; Feng LJ; Liu JL; Eyo UB; Zhou LJ; Mogilevsky R; Wang W; Wu LJ
    J Neurosci; 2017 Aug; 37(33):7878-7892. PubMed ID: 28716963
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recruited mast cells in the tumor microenvironment enhance bladder cancer metastasis via modulation of ERβ/CCL2/CCR2 EMT/MMP9 signals.
    Rao Q; Chen Y; Yeh CR; Ding J; Li L; Chang C; Yeh S
    Oncotarget; 2016 Feb; 7(7):7842-55. PubMed ID: 26556868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-cancer effect of danshen and dihydroisotanshinone I on prostate cancer: targeting the crosstalk between macrophages and cancer cells via inhibition of the STAT3/CCL2 signaling pathway.
    Wu CY; Yang YH; Lin YY; Kuan FC; Lin YS; Lin WY; Tsai MY; Yang JJ; Cheng YC; Shu LH; Lu MC; Chen YJ; Lee KD; Kang HY
    Oncotarget; 2017 Jun; 8(25):40246-40263. PubMed ID: 28157698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Infiltrating macrophages promote prostate tumorigenesis via modulating androgen receptor-mediated CCL4-STAT3 signaling.
    Fang LY; Izumi K; Lai KP; Liang L; Li L; Miyamoto H; Lin WJ; Chang C
    Cancer Res; 2013 Sep; 73(18):5633-46. PubMed ID: 23878190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-androgen enzalutamide enhances prostate cancer neuroendocrine (NE) differentiation via altering the infiltrated mast cells → androgen receptor (AR) → miRNA32 signals.
    Dang Q; Li L; Xie H; He D; Chen J; Song W; Chang LS; Chang HC; Yeh S; Chang C
    Mol Oncol; 2015 Aug; 9(7):1241-51. PubMed ID: 25817444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New therapeutic approach to suppress castration-resistant prostate cancer using ASC-J9 via targeting androgen receptor in selective prostate cells.
    Lai KP; Huang CK; Chang YJ; Chung CY; Yamashita S; Li L; Lee SO; Yeh S; Chang C
    Am J Pathol; 2013 Feb; 182(2):460-73. PubMed ID: 23219429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting of tumour-infiltrating macrophages via CCL2/CCR2 signalling as a therapeutic strategy against hepatocellular carcinoma.
    Li X; Yao W; Yuan Y; Chen P; Li B; Li J; Chu R; Song H; Xie D; Jiang X; Wang H
    Gut; 2017 Jan; 66(1):157-167. PubMed ID: 26452628
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.